Pfizer and Biontech announce the start of testing a vaccine designed to counter the Omicron

Pfizer and Biontech have initiated one studio to evaluate the specific response to Omicron Corona in adults aged 18 to 55 years.

And Pfizer stated in a statement today Tuesday that the first registered participants in clinical trials received an Omicron-based vaccine candidate as an initial two-dose series and a booster dose.

The studio it will include three groups that will study different regimens for the current Pfizer-Biontech or Omicron-based vaccine.

“Current research and real-world data show that enhancers continue to provide a high level of protection against serious illness and hospitalization with OMICRON and we recognize the need to be prepared if this protection decreases over time and can help address OMICRON and new variants. in the future, “continued Pfizer.

“Staying alert for the virus requires us to identify new ways in which people can maintain a high level of protection, “said Catherine Yu Janssen, vice president senior and head of vaccine research and development at Pfizer.

“We believe that the development and research of variant-based vaccines, such as this one, are essential in our efforts to achieve this,” Catherine added.

According to the statement, the vaccines continue to provide strong protection against serious diseases caused by Omicron. However, the emerging data indicate that the vaccine causes protection against infections and that mild to moderate disease resolves more rapidly than observed in previous strains.

For his part, Ugur Sahin, CEO and co-founder of BioNTech, said: “This studio it is part of our scientific approach to developing a variant-based vaccine that achieves a similar level of protection against Omicron as it did with previous variants but with a longer duration of protection. “

The companies previously announced that they plan to produce 4 billion doses of the Pfizer-Biontech vaccine in 2022 and this capacity is not expected to change if a modified vaccine is needed.

Read More About: Business News

Follow AsumeTech on

More From Category

More Stories Today

Leave a Reply